
# CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY INFORMATION

Anne Arundel Health System, Inc. and Subsidiaries Years Ended June 30, 2016 and 2015 With Report of Independent Auditors

Ernst & Young LLP





## Consolidated Financial Statements and Supplementary Information

Years Ended June 30, 2016 and 2015

## Contents

Report of Independent Auditors	1
Audited Consolidated Financial Statements	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	
Consolidated Statements of Cash Flows	
Notes to Consolidated Financial Statements	9
Supplementary Information	
Supplementary Consolidating Balance Sheet	.48
Supplementary Consolidating Schedule of Revenues, Expenses, Gains, and Losses	.50
Anne Arundel Medical Center, Inc. and Subsidiaries:	
Supplementary Consolidating Balance Sheet	.51
Supplementary Consolidating Schedule of Revenues, Expenses, Gains, and Losses	.53
Supplementary Description of Consolidating and Eliminating Entries	.54



Ernst & Young LLP 621 East Pratt Street Baltimore, MD 21202

Tel: +1 410 539 7940 Fax: +1 410 783 3832 ey.com

## Report of Independent Auditors

The Board of Trustees Anne Arundel Health System, Inc.

We have audited the accompanying consolidated financial statements of Anne Arundel Health System, Inc. (a Maryland not-for-profit corporation) and subsidiaries, which comprise the consolidated balance sheets as of June 30, 2016 and 2015, and the related consolidated statements of operations and changes in net assets and cash flows for the years then ended, and the related notes to the consolidated financial statements.

### Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

#### Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We did not audit the financial statements of Cottage Insurance Company, Ltd., a wholly-owned subsidiary, which statements reflect total assets of \$32,318,000 and \$34,229,000 as of June 30, 2016 and 2015, respectively, and net loss after elimination of intercompany revenues of \$1,800,000 and \$1,098,000, respectively, for the years then ended. Those statements were audited by other auditors whose report has been furnished to us, and our opinion, insofar as it relates to the amounts included for Cottage Insurance Company, Ltd., is based solely on the report of the other auditors. We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether



due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Opinion

In our opinion, based on our audits and the report of other auditors, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Anne Arundel Health System, Inc. and subsidiaries as of June 30, 2016 and 2015, and the consolidated results of their operations, changes in their net assets, and their cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

#### **Supplementary Information**

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The supplementary consolidating information is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Ernst + Young LLP

September 30, 2016

## **Consolidated Balance Sheets**

	June 30			
	2016		2015	
Assets				
Current assets:				
Cash and cash equivalents	\$ 77,674,00	0 \$	99,625,000	
Short-term investments	3,796,00	0	2,484,000	
Current portion of assets whose use is limited	14,371,00	0	17,721,000	
Patient receivables, less allowance for uncollectible accounts of \$17,116,000 and \$18,639,000,				
at June 30, 2016 and 2015, respectively	70,639,00	0	61,854,000	
Current portion of pledges receivable, net	1,296,00	0	3,015,000	
Inventories	8,935,00	0	8,130,000	
Prepaid expenses and other current assets	8,214,00	0	6,257,000	
Total current assets	184,925,00	0	199,086,000	
Property and equipment	833,945,00	0	809,488,000	
Less accumulated depreciation and amortization	(389,611,00	0)	(356,402,000)	
Net property and equipment	444,334,00	0	453,086,000	
Other assets:				
Investments	246,824,00	0	253,285,000	
Investments in joint ventures	8,717,00	0	8,310,000	
Pledges receivable, net of current portion and net of allowance for uncollectible pledges of \$402,000 and \$497,000, at June 30, 2016 and				
2015, respectively	5,037,00	0	4,404,000	
Assets whose use is limited	50,442,00	0	51,566,000	
Deferred debt issue costs, net of accumulated amortization of \$1,470,000 and \$1,195,000,				
at June 30, 2016 and 2015, respectively	4,370,00		4,645,000	
Restricted collateral for interest rate swap contract	69,336,00		62,939,000	
Other assets	18,033,00		16,800,000	
Total assets	<u>\$ 1,032,018,00</u>	0 \$	1,054,121,000	

## Consolidated Balance Sheets (continued)

	June 30		
	2016	2015	
Liabilities and net assets			
Current liabilities:			
Accounts payable	\$ 19,011,000	\$ 19,485,000	
Accrued salaries, wages, and benefits	27,285,000	39,465,000	
Other accrued expenses	24,655,000	23,034,000	
Line of credit			
Current portion of long-term debt	15,974,000	12,222,000	
Advances from third-party payors	22,001,000	22,465,000	
Total current liabilities	108,926,000	116,671,000	
Long-term debt, less current portion and unamortized original issue premium Interest rate swap contracts Accrued pension liability Other long-term liabilities Total liabilities	396,776,000 99,585,000 31,468,000 <u>19,667,000</u> 656,422,000	413,310,000 65,852,000 22,702,000 20,511,000 639,046,000	
Net assets:			
Unrestricted	351,518,000	389,579,000	
Temporarily restricted	13,028,000	14,364,000	
Permanently restricted	11,050,000	11,132,000	
Total net assets	375,596,000	415,075,000	
Total liabilities and net assets	<u>\$ 1,032,018,000</u>	\$ 1,054,121,000	

See accompanying notes.

## Consolidated Statements of Operations and Changes in Net Assets

	Year Ended June 30		
	2016 2015		
Operating revenue:			
Net patient service revenue	\$ 651,863,000	\$ 624,656,000	
Provision for bad debts	(16,122,000)	(19,431,000)	
Net patient service revenue, less provision for bad debts	635,741,000	605,225,000	
Other operating revenue	31,948,000	28,480,000	
Total operating revenue	667,689,000	633,705,000	
Operating expenses:			
Salaries and wages	291,455,000	272,891,000	
Employee benefits	43,376,000	42,925,000	
Supplies	140,001,000	129,398,000	
Purchased services	119,101,000	112,348,000	
Depreciation and amortization	35,377,000	36,267,000	
Interest	13,340,000	14,427,000	
Total operating expenses	642,650,000	608,256,000	
Operating income	25,039,000	25,449,000	
Other income (loss):			
Investment income, net	14,391,000	16,584,000	
Income from joint ventures and other, net	23,000	1,895,000	
Loss on advance refunding of debt	<i>,</i> –	(32,230,000)	
Change in unrealized losses on trading securities, net	(19,569,000)	(16,031,000)	
Realized and unrealized losses on interest rate swap			
contracts, net	(40,055,000)	(16,637,000)	
Total other (loss) income, net	(45,210,000)	(46,419,000)	
Revenues and gains in excess of (less than) expenses	\$ (20,171,000)	\$ (20,970,000)	

## Consolidated Statements of Operations and Changes in Net Assets (continued)

	Year Ended June 30		
	2016 2015		
Unrestricted net assets			
Revenues and gains in excess of (less than) expenses	\$ (20,171,000)	\$ (20,970,000)	
Pension liability adjustment	(20,069,000)	(11,683,000)	
Net assets released from restrictions used for purchase			
of property and equipment	2,340,000	3,177,000	
Transfers and other, net	(161,000)	1,039,000	
Decrease in unrestricted net assets	(38,061,000)	(28,437,000)	
		· · · · /	
Temporarily restricted net assets			
Contributions and pledges	7,993,000	4,669,000	
Change in net unrealized gains and losses on investments	(1,180,000)	(1,333,000)	
Temporarily restricted investment income	365,000	387,000	
Net assets released from restrictions	(11,646,000)	(7,763,000)	
Transfers and other, net	3,132,000	1,770,000	
Decrease in temporarily restricted net assets	(1,336,000)	(2,270,000)	
Permanently restricted net assets			
Contributions for endowment funds	144,000	57,000	
Transfers of interest income and other, net	(226,000)	(222,000)	
Decrease in permanently restricted net assets	(82,000)	(165,000)	
Decrease in net assets	(39,479,000)	(30,872,000)	
Net assets at beginning of year	415,075,000	445,947,000	
Net assets at end of year	\$ 375,596,000	\$ 415,075,000	

See accompanying notes.

## Consolidated Statements of Cash Flows

	Year Ended June 30		
	2016	2015	
<b>Operating activities</b> Decrease in net assets	Φ ( <b>20 470 000</b> )	¢ (20.972.000)	
	\$ (39,479,000)	\$ (30,872,000)	
Adjustments to reconcile decrease in net assets to net cash			
provided by operating activities:	20 751 000	17 264 000	
Change in net unrealized losses on investments	20,751,000	17,364,000	
Realized and unrealized losses on interest rate swap	40.055.000	16 627 000	
contracts, net	40,055,000	16,637,000	
Pension liability adjustment	20,069,000	11,683,000	
Equity in earnings of joint ventures and other	(407,000)	(332,000)	
Distributions received from joint ventures	- (9.127.000)	145,000	
Restricted contributions and pledges, net	(8,137,000)	(4,726,000)	
Loss on advance refunding of debt	-	32,230,000	
Depreciation and amortization	35,377,000	36,267,000	
Restricted investment income	(365,000)	(387,000)	
Increase in investments – trading	(15,602,000)	(17,518,000)	
Decrease in assets whose use is limited, net – trading	4,395,000	3,565,000	
Net change in operating assets and liabilities	(35,801,000)	(1,009,000)	
Net cash provided by operating activities	20,856,000	63,047,000	
Investing activities			
Purchases of property and equipment	(26,350,000)	(14,645,000)	
Decrease in assets whose use is limited – other than trading	79,000	4,267,000	
Change in collateralization and payments on interest rate swaps	(12,719,000)	(17,734,000)	
Net cash used in investing activities	(38,990,000)	(28,112,000)	
- · · · · · · · · · · · · · · · · · · ·	(00) (00)	(==;===;==;==;	
Financing and fundraising activities			
Net proceeds from issuance of Series 2014 Revenue Bonds	-	134,825,000	
Repayments of long-term debt	(13,405,000)	(35,456,000)	
Advance refunding of Series 2009A Revenue Bonds	-	(116,440,000)	
Payments for deferred financing costs	-	(1,899,000)	
Restricted contributions received and other	9,223,000	7,105,000	
Restricted income received	365,000	387,000	
Net cash used in financing and fundraising activities	(3,817,000)	(11,478,000)	
Net (decrease) increase in cash and cash equivalents	(21,951,000)	23,457,000	
Cash and cash equivalents at beginning of year	99,625,000	76,168,000	
Cash and cash equivalents at beginning of year	\$ 77,674,000	\$ 99,625,000	
Cash and cash equivalents at the Orytai	φ //,0/4,000	ψ 77,023,000	

## Consolidated Statements of Cash Flows (continued)

	Year Ended June 30		
	2016	2015	
Changes in operating assets and liabilities			
Increase (decrease) in operating assets:			
Patient receivables, net	\$ (8,785,000)	\$ 6,768,000	
Inventories	(805,000)	(8,000)	
Prepaid expenses and other	(1,957,000)	715,000	
Other assets	(610,000)	(3,891,000)	
	(12,157,000)	3,584,000	
(Decrease) increase in operating liabilities:			
Accounts payable	(474,000)	(887,000)	
Accrued salaries, wages, and benefits	(12,180,000)	7,019,000	
Other accrued expenses	1,621,000	2,408,000	
Advances from third-party payors	(464,000)	(2,779,000)	
Other long-term liabilities	(12,147,000)	(10,354,000)	
	(23,644,000)	(4,593,000)	
Net change in operating assets and liabilities	\$ (35,801,000)	\$ (1,009,000)	
Supplemental disclosures of cash flow information			
Cash paid for interest	<u>\$ 12,818,000</u>	\$ 15,258,000	

See accompanying notes.

### Notes to Consolidated Financial Statements

#### June 30, 2016

#### 1. Organization and Basis of Presentation

Anne Arundel Health System, Inc. (the Parent or the System) is a Maryland not-for-profit corporation. The Parent has the following wholly owned subsidiaries: Anne Arundel Medical Center, Inc. (the Hospital) and its subsidiaries; Anne Arundel Health Care Services, Inc. (HCS); Cottage Insurance Company, Ltd. (Cottage); and Anne Arundel General Treatment Services, Inc. (GTS); Anne Arundel Health System Research Institute, Inc. (RI); Anne Arundel Medical Center Foundation, Inc. (the Foundation); Anne Arundel Health Care Enterprises, Inc. (HCE); Physician Enterprise, LLC (PE) and its subsidiaries; Anne Arundel Physician Group, LLC (AAPG); AAMG Physical Therapy, LLC; Community Clinics, LLC; Anne Arundel FastCare, LLC; Orthopedic Physicians of Annapolis (OPA); Anne Arundel Medical Center Collaborative Care Network, LLC; Anne Arundel Real Estate Holding Company, Inc. (the Real Estate Company) and its subsidiaries; Pavilion Park, Inc. (PPI); Annapolis Exchange Lot IV, LLC; Annapolis Exchange Lot V, LLC; and Blue Building, LLC. The accompanying consolidated financial statements include the accounts of the Parent and its wholly owned subsidiaries (collectively, the Group). All significant intercompany accounts and transactions have been eliminated in consolidation. The Real Estate Company and PPI own a 42.84% interest in Kent Island Medical Arts, LLC (KIMA), a limited liability company that owns and operates a medical office building. PPI is the managing member of KIMA and has substantive participation rights in KIMA. The financial statements of KIMA are consolidated in the accompanying consolidated financial statements. The non-controlling interest in KIMA was 57.16% as of June 30, 2016 and 2015. This interest was \$970,000 and \$981,000 at June 30, 2016 and 2015, respectively, and is included within unrestricted net assets in the accompanying consolidated balance sheets.

#### 2. Summary of Significant Accounting Policies

#### **Reclassification of Prior Year Presentation**

Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations. Purchased services and professional fees have been consolidated into purchased services.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### **Cash and Cash Equivalents**

Cash and cash equivalents include cash held in checking and savings accounts, money market accounts, and short-term certificates of deposit with original maturities of 90 days or less. Cash balances and collateral held by a counterparty are principally uninsured and are subject to normal credit risks. At June 30, 2016 and 2015, and at various times during the year, the System maintained cash-in-bank balances in excess of the \$250,000 federally insured limits.

#### **Derivative Instruments**

On May 10, 2006, the Hospital entered into a forward variable-to-fixed interest rate swap agreement with an effective date of November 1, 2008. This contract was also entered into in an effort to reduce the risk of variable interest rate debt and has a term through July 1, 2048. Under Accounting Standards Codification (ASC) 815, *Derivatives and Hedging*, the Hospital has recognized its derivative instruments as either assets or liabilities in the accompanying consolidated balance sheets at fair value. As these derivative instruments are not designated as hedges, the unrealized gain or loss on these contracts has been recognized in the accompanying consolidated statements of operations and changes in net assets as realized and unrealized gains (losses) on interest rate swap contracts, net. The fair market values of the derivative instruments include a credit valuation adjustment (CVA) as required by ASC 820, *Fair Value Measurements and Disclosures*. When applying the CVA, the valuation of the variable-to-fixed interest rate swap contract was decreased by \$1,801,000 and \$761,000 as of June 30, 2016 and 2015, respectively.

On March 23, 2016, in an effort to reduce the amount of restricted cash pledged as collateral with the original counterparty, the Hospital entered into a Novation Agreement with a second counterparty. Immediately prior to the Novation Agreement, the System modified the existing swap to bifurcate the existing swap into a five-year swap with the remainder into a 2021 through 2048 swap. The terms of the bifurcated swap remain identical to the original swap. The Novation Agreement resulted in the return of \$29,164,000 as of June 30, 2016.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

A summary of the Hospital's derivative instruments and related activity at June 30, 2016 and 2015, and for the years then ended, is as follows:

Description of Derivative Instrument	2016 Fair Value Liability
Variable-to-fixed interest rate swap contract (maturity date) Variable-to-fixed interest rate swap contract (maturity date)	\$ (26,849,000) (72,736,000) \$ (99,585,000)
<b>Description of Derivative Instrument</b>	2015 Fair Value Liability
Variable-to-fixed interest rate swap contract	\$ (65,852,000)

The change in unrealized losses recognized in revenues and gains in excess of (less than) expenses for the year ended June 30, 2016 and June 30, 2015 were \$33,733,000 and \$10,226,000, respectively.

At June 30, 2016 and 2015, the net termination value (i.e., mark-to-market value) of the derivative instruments totaled \$101,386,000 and \$68,455,000, respectively. The Hospital may be exposed to credit loss in the event of nonperformance by the other party to the interest rate swap agreements, the risk of which is reflected in the fair value of the instruments under ASC 820. However, the Hospital does not anticipate nonperformance by the counterparty.

During fiscal year 2016, the Hospital paid net payments under its interest rate swap program of \$6,322,000. In fiscal year 2015, the Hospital paid net payments under its interest rate swap program of \$6,411,000. These amounts are included within realized and unrealized gains (losses) on interest rate swap contracts, net in the accompanying consolidated statements of operations and changes in net assets and within investing activities in the accompanying consolidated statements of cash flows.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

Under the derivative contract for the 2021 through 2048 swap, the Hospital must transfer collateral for the benefit of the counterparty, to the extent that the termination values exceed certain limits. The Hospital's collateral requirement for the benefit of the counterparty was approximately \$69,336,000 and \$62,939,000 at June 30, 2016 and 2015, respectively. The ongoing mark-to-market values and resulting collateral requirements of the Hospital's interest rate swap contract are subject to variability based on market factors (primarily changes in interest rates). Collateral requirements under this interest rate swap contract are excluded from unrestricted cash and investments for purposes of determining the System's compliance with its liquidity covenants under its Maryland Health and Higher Educational Facilities Authority (MHHEFA or the Authority) revenue bond agreements and its derivative agreements. Collateral amounts are included in noncurrent assets in the accompanying consolidated balance sheets. Approximately \$8,428,000 and \$3,657,000 were due to the financial institution as of June 30, 2016 and 2015, respectively.

The amount due is included in other accrued expenses in the accompanying consolidated balance sheet as of June 30, 2016, and is reflected within investing activities in the accompanying consolidated statements of cash flows.

#### Assets Whose Use is Limited and Investments

Assets whose use is limited are principally comprised of certain funds established to be held and invested by a trustee. These funds are related to the issuance of the Hospital's revenue bonds, investments held at Cottage, and certain permanently restricted endowment assets.

The fair values of publicly traded securities and mutual funds are based on quoted market prices of individual securities or investments or estimated amounts using quoted market prices of similar investments. Hedge fund investments, some of which are structured so that the System holds limited partnership interests, are stated at fair value as estimated in an unquoted market. Valuations of these investments, and therefore the System's holdings, may be determined by the investment manager or general partner and for fund-of-funds investments are primarily based on financial data supplied by the underlying investee funds. Values may be based on historical cost, appraisals, or other estimates that require varying degrees of judgment. Investment income or loss from all unrestricted investments is included in the accompanying consolidated statements of operations and changes in net assets as part of other income (loss).

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

Investment income or loss on investments of temporarily and permanently restricted assets is added to or deducted from the appropriate restricted fund balance if the income is restricted. The cost of securities sold is based on the specific-identification method.

All investment balances are principally uninsured and subject to normal credit risk. Investments are classified as either current or noncurrent based on the maturity dates and the availability for current operations. Investments included in noncurrent assets consist of Board-designated investment funds of \$245,271,000 and \$251,672,000 as of June 30, 2016 and 2015, respectively. Based on the System's investment policy, such amounts could be liquidated, at the discretion of the Board, to satisfy short-term requirements.

Substantially all investments, other than borrowed funds required to be expended for capital projects, are classified as trading securities, with unrealized gains and losses included in revenues and gains in excess of (less than) expenses.

Borrowed funds required to be expended for capital projects are classified as other-than-trading and are included in assets whose use is limited.

#### **Patient Receivables and Allowances**

The Group's policy is to write off all patient accounts that have been identified as uncollectible. An allowance for doubtful accounts is recorded for accounts not yet written off that are anticipated to be uncollectible in future periods. When determining the allowance, the Group's policy considers the probability of recoverability of accounts based on past experience, taking into account the current collection trends. Credit risks are assessed based on historical write-offs, net of recoveries, as well as an analysis of aged accounts receivable balances with allowances generally increasing as the receivable ages. The analysis of receivables is performed monthly, and the allowances are adjusted accordingly.

Insurance coverage and credit information are obtained from patients, when available. No collateral is obtained for accounts receivable.

Accounts receivable from third-party payors have been adjusted to reflect the difference between the charges and the estimated reimbursable amounts.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### Inventories

Inventories, which primarily consist of medical supplies and drugs, are carried at the lower of cost or market. Cost is determined using the first-in, first-out method.

#### **Property and Equipment**

Property and equipment are stated at cost. Included in computers and software are capitalized labor costs of \$10,950,000 and \$10,696,000 as of June 30, 2016 and 2015, respectively. Depreciation and amortization, including amortization of assets recorded under capital leases, are recorded on the straight-line method over the estimated useful lives of the assets.

The following is a summary of property and equipment, stated at cost:

	Estimated	June 30		
	Useful Lives	2016	2015	
Land		\$ 14,068,000	\$ 13,151,000	
Land improvements	20 years	22,016,000	22,016,000	
Buildings and improvements	20-40 years	475,001,000	471,322,000	
Fixed equipment	5–20 years	9,854,000	9,720,000	
Leasehold improvements	5–10 years	51,093,000	50,184,000	
Movable equipment	7–10 years	183,639,000	177,387,000	
Computers and software	3–5 years	69,880,000	62,351,000	
Construction-in-progress	-	8,394,000	3,357,000	
		\$ 833,945,000	\$ 809,488,000	

Construction-in-progress consists of direct costs associated with hospital department renovations, certain leasehold improvements, and smaller capital projects. As these projects are completed, the related assets are transferred out of construction-in-progress and into the appropriate asset category and are depreciated over the applicable useful lives.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### **Investments in Joint Ventures**

The System accounts for its investments in joint ventures using the equity method of accounting. During 2011, the Real Estate Company and another party formed West County, LLC, a joint venture that owns and operates a medical office building that opened in December 2012. The Real Estate Company has a 50% interest in this joint venture, with each owner's investment being \$8,306,000 and \$7,933,000 as of June 30, 2016 and 2015, respectively.

#### **Deferred Debt Issuance Costs**

Administrative, legal, financing, underwriting discount, and other miscellaneous expenses that were incurred in connection with debt financings were deferred and are being amortized over the lives of the bond issues using the straight-line method, which approximates the effective-interest method in all material respects. The amortization expense of the deferred debt issue costs was \$275,000 and \$310,000 for the years ended June 30, 2016 and 2015, respectively.

#### **Temporarily and Permanently Restricted Net Assets**

Temporarily restricted net assets are those whose use by the Group has been limited by donors to a specific time period or purpose. Substantially all temporarily restricted net assets in the accompanying consolidated financial statements are restricted to fund certain Hospital capital additions and operating programs. Permanently restricted net assets have been restricted by donors to be maintained in perpetuity. The income from these funds is expendable to support health care services.

#### **Net Patient Service Revenue**

Net patient service revenue is reported at the estimated net realizable amounts from patients, thirdparty payors, and others for services rendered. This includes regulatory discounts allowed to Blue Cross, Medicare, Medicaid, and other third-party payors and charity care.

During 2016 and 2015, approximately 35% and 36%, respectively, of net patient service revenue were received under the Medicare program, with 30% and 29% from Blue Cross and 29% and 30% from contracts with other third parties, respectively, and 6% from other sources.

### Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

The following table sets forth the detail of net patient service revenue:

	Year Ended June 30		
	2016	2015	
Gross patient service revenue	\$ 812,915,000	\$ 772,094,000	
Revenue deductions:			
Charity care	4,457,000	3,202,000	
Contractual and other allowances	156,595,000	144,236,000	
Net patient service revenue	651,863,000	624,656,000	
Less provision for bad debts	16,122,000	19,431,000	
Net patient service revenue, less provision			
for bad debts	\$ 635,741,000	\$ 605,225,000	

Patient accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the collectibility of accounts receivable, the Hospital analyzes its past history and identifies trends to estimate the appropriate allowance for doubtful accounts and a provision for bad debts. For receivables associated with services provided to patients who have third-party coverage, the Hospital analyzes contractually due amounts and provides an allowance for doubtful accounts and a provision for bad debts, if necessary. For receivables associated with self-pay patients (which includes both patients without insurance and patients with deductible and co-payment balances due for which third-party coverage exists for part of the bill), the Hospital records a provision for bad debts in the period of service on the basis of its past experience. The difference between the approved rates and the amounts actually collected after all reasonable collection efforts have been exhausted is charged off against the allowance for doubtful accounts. The Hospital has not changed its charity care or uninsured discount policies during fiscal years 2016 or 2015.

A substantial amount of the Group's revenues is received from health maintenance organizations and other managed-care payors. Managed-care payors generally use case management activities to control hospital utilization. These payors also have the ability to select health care providers offering the most cost-effective care. Management does not believe that the Group has undue exposure to any one managed-care payor.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

The Hospital's revenues may be subject to adjustment as a result of examination by government agencies or contractors and as a result of differing interpretations of government regulations, medical diagnoses, charge coding, medical necessity, or other contract terms. The resolution of these matters, if any, often is not finalized until subsequent to the period during which the services were rendered.

The Group employs physicians in several hospital-based specialties (including, but not limited to, obstetrics, intensive care, and hospitalists). Net physician revenue is recognized when the services are provided and recorded at the estimated net realizable amount based on the contractual arrangements with third-party payors and the expected payments from the third-party payors and the patients. The difference between the billed charges and the estimated net realizable amounts are recorded as a reduction in physician revenue when the services are provided. The System recognized net physician revenue of \$100,500,000 and \$84,436,000 for the years ended June 30, 2016 and 2015, respectively. At June 30, 2016 and 2015, \$7,650,000 and \$7,058,000, respectively, of net physician accounts receivable are included in patient receivables in the accompanying consolidated balance sheets.

#### **Charity Care**

The Group provides charity care to patients who meet certain criteria established under its charity care guidelines. Because members of the Group do not pursue the collection of amounts determined to qualify as charity care, they are not reported as revenue in the accompanying consolidated statements of operations and changes in net assets. The direct and indirect costs associated with providing this care are \$3,290,000 and \$2,338,000 for the years ended June 30, 2016 and 2015, respectively. These costs are calculated by applying a ratio of operating expenses over gross patient charges to the charity care provided at established rates. The state of Maryland's rate system includes components within the rates to partially compensate hospitals for uncompensated care.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### **Other Operating Revenue**

Other operating revenue is comprised of grant revenue, incentive payments related to the implementation and meaningful use of certified electronic health records (EHRs), cafeteria revenue, net assets released from restrictions for operating purposes, and other miscellaneous items.

The American Recovery and Reinvestment Act of 2009 provides for Medicare and Medicaid incentive payments beginning in 2011 for eligible hospitals and professionals that implement and achieve meaningful use of certified EHR technology that demonstrates improved quality and effectiveness of care. Eligibility for annual Medicare incentive payments depends on providers demonstrating meaningful use of EHR technology in each period over a four-year period. An additional Medicaid incentive payment is available to providers that adopt, implement, or upgrade certified EHR technology. However, in order to receive additional Medicaid incentive payments in subsequent years, providers must demonstrate continued meaningful use of EHR technology.

For Medicare and Medicaid EHR incentive payments, the Hospital utilizes a grant accounting model to recognize these revenues. Under this accounting policy, EHR incentive payments were recognized as revenues when attestation that the EHR meaningful use criteria for the required period of time was demonstrated. The System recognized \$983,000 and \$2,081,000 of EHR revenue for the years ended June 30, 2016 and 2015, respectively.

The System's attestation of compliance with the meaningful use criteria is subject to audit by the federal government or its designee. The recognition of grant income is based on management's best estimate and the amounts recognized are subject to change. Any subsequent changes in the recognition of the grant income will impact the results of operations in the period in which they occur.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### **Donations and Bequests**

Unconditional promises to give cash and other assets are reported at fair value on the date the promise is received. Conditional promises to give, and indications of intentions to give, are reported at fair value on the date the gift is received. The gifts are reported as either temporarily or permanently restricted if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or a purpose restriction is accomplished, temporarily restricted net assets are reclassified as unrestricted net assets in the accompanying consolidated statements of operations and changes in net assets. Donor-restricted contributions whose restrictions are met within the same year as received are reported as unrestricted contributions in the accompanying consolidated financial statements. Contributions that are unrestricted are reflected as other operating revenue in the accompanying consolidated statements of operating revenue in the accompanying consolidated statements.

Scheduled payments for pledges receivable for the years ending June 30 are as follows:

2017	\$ 2,511,000
2018–2020	2,636,000
2021 and thereafter	1,801,000
Less:	
Impact of discounting pledges receivable to net present value	(213,000)
Allowance for uncollectible pledges	 (402,000)
Net pledges receivable	\$ 6,333,000

Pledges receivable are discounted using rates between 0.6% and 2.0%.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### **Revenues and Gains in Excess of (Less Than) Expenses**

The accompanying consolidated statements of operations and changes in net assets include revenues and gains in excess of (less than) expenses. Changes in unrestricted net assets that are excluded from revenues and gains in excess of (less than) expenses, consistent with industry practice, include contributions received and used for additions of long-lived assets and certain changes in pension liabilities.

#### **Group Purchasing Organization Initial Public Offering**

The Hospital has participated and owned equity in the Premier Limited Partnership (Premier), which has served as a group purchasing organization for many years. This participation provides purchasing contract rates and rebates the System would not be able to obtain on its own. The Hospital accounts for its investment in Premier using the equity method of accounting.

During the year ended June 30, 2014, Premier restructured from a privately held company to a public company in an initial public offering (IPO) and several financial transactions have occurred with those holding equity in Premier before the IPO, including the System. As a result, the System received a cash payment of approximately \$1,500,000 in exchange for 16% of its previous ownership in Premier. In addition, in exchange for the extension of the group purchasing contract, the System received partial ownership of the new public Company (the Class B units).

The System received 309,580 Class B units that are earned in seven separate tranches over an 85-month period ending October 31, 2020. This investment is reflected in other assets in the consolidated balance sheets. The opportunity will exist in the future for these Class B units to be converted to the Premier public company stock. Prior to vesting, the Class B units may be transferred or sold with the approval of Premier. During the years ended June 30, 2016 and 2015, the System recognized approximately \$1,243,000 and \$1,891,000, respectively, of income related to Tranches 2 and 3 of the Class B units which is included as a reduction of supplies expense in the consolidated statement of operations and changes in net assets. The value of the Class B units is tied to the Group purchasing contract and is considered a vendor incentive.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### **Income Tax Status**

The Parent, the Hospital, the Foundation, HCS, GTS, PE, and RI have received determination letters from the Internal Revenue Service (IRS) stating that they are exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code. The Real Estate Company has received a determination letter from the IRS stating that it is exempt from federal income taxes under Section 501(c)(2) of the Internal Revenue Code.

HCE and PPI are subject to federal and state income taxes. These income taxes are immaterial to the financial statements.

Certain limited liability companies within the consolidated group are not subject to income taxes. Taxable income or loss is passed through to and reportable by the members individually.

Under the Cayman Islands Tax Concessions Law (Revised), the Governor-in-Cabinet issued an undertaking regarding Cottage on November 29, 2005, exempting it from all local income, profit, or capital gains taxes. The undertaking has been issued for a period of 20 years and, at the present time, no such taxes are levied in the Cayman Islands. Accordingly, no provision for taxes is made in these consolidated financial statements.

Under the requirements of ASC 740, *Income Taxes*, tax-exempt organizations could be required to record an obligation as the result of a tax position they have historically taken on various tax exposure items. The Group has determined that it does not have any uncertain tax positions through June 30, 2016.

#### **Use of Estimates**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

#### **Recent Accounting Pronouncements**

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, *Revenue from Contracts with Customers (Topic 606)*. This guidance is intended to improve and converge with the international standards and the financial reporting requirements for revenue from contracts with customers. In August 2015, the FASB issued ASU No. 2015-14, *Revenue from Contracts with Customers (Topic 606)*, which extends the effective date originally contemplated by ASU 2014-09. The revised standards will be effective for fiscal year 2019 and early adoption is permitted beginning in fiscal year 2018. Management has not yet determined the impact the adoption of this new accounting pronouncement will have on its consolidated financial statements.

In August 2014, the FASB issued ASU No. 2014-15, *Presentation of Financial Statements* — *Going Concern (Subtopic 205-40)*, which provides guidance in GAAP about management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. This amendment should reduce diversity in the timing and content of footnote disclosures. This ASU is effective for fiscal year 2017. The guidance is not expected to materially impact the System's consolidated results of operations, net assets, or cash flows.

In April 2015, the FASB issued ASU No. 2015-03, *Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.* The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This guidance is effective for fiscal year 2017. The guidance is not expected to materially impact the System's consolidated results of operations, net assets, or cash flows.

In April 2015, the FASB issued ASU No. 2015-05, *Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer's Accounting for Fees Paid in a Cloud Computing Arrangement*, which provides guidance to clarify the customer's accounting for fees paid in a cloud computing arrangement and also eliminates today's requirement that customers analogize to the leases standard when determining the asset acquired in a software licensing arrangement. This guidance is effective for fiscal year 2017. The guidance is not expected to materially impact the System's consolidated results of operations, net assets, or cash flows.

## Notes to Consolidated Financial Statements (continued)

#### 2. Summary of Significant Accounting Policies (continued)

In February 2016, the FASB issued ASU No. 2016-02, *Leases*. This ASU amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets. This guidance is effective for fiscal year 2020. The System is currently assessing the potential impact this ASU will have on the System's consolidated results of operations, financial position, and cash flows.

#### **3. Regulatory Environment**

#### Medicare and Medicaid

The Medicare and Medicaid reimbursement programs represent a substantial portion of the Group's revenues. The Group's operations are subject to numerous laws and regulations of federal, state, and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government health care program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Over the past several years, government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by health care providers. Violations of these laws and regulations could result in expulsion from government health care programs, together with the imposition of fines and penalties, as well as repayments for patient services previously billed. Compliance with fraud and abuse standards and other government regulations can be subject to future government review and interpretation. Also, future changes in federal and state reimbursement funding mechanisms and related government budgeting constraints could have an adverse effect on the Group.

In 1983, Congress approved a Medicare prospective payment plan for most inpatient services as part of the Social Security Amendment Act of 1983. Hospitals in Maryland were granted a waiver from the Medicare prospective payment system under Section 1814(b) of the Social Security Act. The waiver would remain in effect as long as the Maryland rate of increase in payments per admission remained below the national average rate of increase.

In January 2014, the Centers for Medicare and Medicaid Services approved a modernized waiver that includes both inpatient and outpatient revenue. The new waiver will be in place as long as Maryland hospitals achieve significant quality improvements and limit the per capita growth for all payors for Maryland residents. The Medicare per capita spending target is expected to produce cumulative Medicare savings of \$330,000,000 over the five-year period through 2018.

## Notes to Consolidated Financial Statements (continued)

#### **3. Regulatory Environment (continued)**

#### Maryland Health Services Cost Review Commission

The Hospital's rate structure for all hospital-based services is subject to review and approval by the Maryland Health Services Cost Review Commission (HSCRC or the Commission). Under the HSCRC rate-setting system, the Hospital's inpatient and outpatient charges are the same for all patients, regardless of payor, including Medicare and Medicaid.

Beginning in fiscal year 2014, the Hospital entered into an agreement with the HSCRC to participate in the Global Budget Revenue (GBR) program. The GBR model is a revenue constraint and quality improvement system to provide hospitals with strong financial incentives to manage their resources efficiently and effectively in order to slow the rate of increase in health care costs and improve health care delivery processes and outcomes. Under the GBR, total revenue is capped at a predetermined fixed amount. The annual approved revenue is calculated using a permanent base revenue with positive or negative adjustments for inflation, assessments, performance in quality-based programs, infrastructure requirements, and population. Revenue may also be adjusted annually for market share levels and shifts of regulated services to unregulated settings.

The Commission's rate-setting methodology compares the approved rate with the actual average rate charged. Any overcharges or undercharges are settled in future revenue determinations on an annual basis. For the current fiscal year, the Hospital was within the allowed corridors for charging.

The Hospital's policy is to recognize revenue based on actual charges for services to patients in the year in which the services are performed. The Hospital's revenues may be subject to adjustment as a result of examination by government agencies or contractors, and as a result of differing interpretation of government regulations, medical diagnoses, charge coding, medical necessity, or other contract terms. The resolution of these matters, if any, often is not finalized until a subsequent period than which the services were rendered.

## Notes to Consolidated Financial Statements (continued)

#### 4. Investments

Investments, including assets whose use is limited, are stated at fair value. Borrowed funds that are required to be expended on specified capital projects under MHHEFA revenue bond agreements are classified as available for sale. All other investments and assets whose use is limited are classified as trading securities.

	June 30		
	2016		2015
Assets whose use is limited:			
Endowment assets:			
Cash and cash equivalents	\$ 1,182,000	\$	916,000
Equity mutual funds	8,503,000		10,628,000
Fixed income mutual funds	5,348,000		4,367,000
	 15,033,000		15,911,000
Amounts held by trustee:			
Cash and cash equivalents	12,090,000		14,346,000
U.S. government obligations	12,943,000		13,456,000
	 25,033,000		27,802,000
Amounts held by Cottage:			
Cash and cash equivalents	2,061,000		2,647,000
Equity mutual funds	8,897,000		8,915,000
Fixed income mutual funds	12,310,000		12,413,000
Hedge funds	1,479,000		1,599,000
	 24,747,000		25,574,000
Total assets whose use is limited	 64,813,000		69,287,000
Less current portion	14,371,000		17,721,000
-	\$ 50,442,000	\$	51,566,000

## Notes to Consolidated Financial Statements (continued)

### 4. Investments (continued)

Amounts held by the trustee are broken down as follows:

	June 30				
	2016	2015			
Bond indenture	\$ 25,033,000	\$ 27,802,000			
Other investments: Cash and cash equivalents	\$ 3,825,000	\$ 2,498,000			
Equity mutual funds	137,938,000	114,373,000			
Fixed income mutual funds	97,137,000	126,230,000			
Hedge funds	11,720,000	12,668,000			
-	250,620,000	255,769,000			
Less short-term investments	3,796,000	2,484,000			
Investments	\$ 246,824,000	\$ 253,285,000			

The components of investment income, net are as follows:

		June 30				
	20	2016 2015				
Interest and dividend income, net Realized gains, net	· · · · · · · · · · · · · · · · · · ·	900,000 91,000	\$ 11,680,000 4,904,000			
	\$ 14,3	91,000	\$ 16,584,000			

## Notes to Consolidated Financial Statements (continued)

#### 5. Fair Value Measurements

ASC 820 defines fair value and establishes a framework for measuring fair value in accordance with U.S. generally accepted accounting principles. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

Level 1 – Defined as observable inputs, such as quoted prices in active markets

*Level 2* – Defined as inputs other than quoted prices in active markets that are either directly or indirectly observable

Level 3 – Defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

The methods described above may produce a fair value calculation that may not be indicative of the net realizable value or reflective of future fair values. Furthermore, while the Group believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

ASC 820 requires that the fair value of derivative contracts include adjustments related to the credit risks of both parties associated with the derivative transactions. The fair value of the Group's derivative contracts reflected in the accompanying consolidated financial statements includes adjustments related to the credit risks of the parties to the transactions.

## Notes to Consolidated Financial Statements (continued)

#### **5.** Fair Value Measurements (continued)

The following tables present the fair value hierarchy for the Group's financial assets and liabilities measured at fair value on a recurring basis at June 30, 2016 and 2015.

	June 30, 2016							
		Total		Quoted Prices in ctive Markets for Identical <u>Assets</u> Level 1		Significant Other Observable Inputs Level 2	τ	Significant Jnobservable Inputs Level 3
Assets								
Cash and cash equivalents Trading securities and assets	\$	77,674,000	\$	77,674,000	\$	-	\$	-
whose use is limited:								
Cash and cash equivalents		19,158,000		12,090,000		7,068,000		_
Equity securities		155,338,000		146,441,000		8,897,000		-
Fixed income securities		114,795,000		102,485,000		12,310,000		_
U.S. Government obligation								
securities		12,943,000		-		12,943,000		-
Hedge funds		13,199,000				13,199,000		
Total		315,433,000		261,016,000		54,417,000		-
Collateral for interest rate swap:								
Cash and cash equivalents	<u> </u>	69,336,000		69,336,000				
Total assets	\$	462,443,000	\$	408,026,000	\$	54,417,000	\$	_
Liabilities								
Derivative instruments	\$	(99,585,000)	\$	_	\$	(99,585,000)	\$	_
Total liabilities	\$	(99,585,000)	\$	_	\$	(99,585,000)		_

### Notes to Consolidated Financial Statements (continued)

#### **5.** Fair Value Measurements (continued)

	June 30, 2015						
				Quoted Prices in ctive Markets for Identical Assets		Significant Other Observable Inputs	Significant nobservable Inputs
		Total		Level 1		Level 2	Level 3
Assets							
Cash and cash equivalents	\$	99,625,000	\$	99,625,000	\$	_	\$ _
Trading securities and assets							
whose use is limited:							
Cash and cash equivalents		20,406,000		14,346,000		6,060,000	_
Equity securities		133,916,000		125,001,000		8,915,000	_
Fixed income securities		143,011,000		130,598,000		12,413,000	_
U.S. Government obligation							
securities		13,456,000		_		13,456,000	_
Hedge funds		14,267,000		_		14,267,000	
Total		325,056,000		269,945,000		55,111,000	—
Collateral for interest rate swap:							
Cash and cash equivalents		62,939,000		62,939,000		_	
Total assets	\$	487,620,000	\$	432,509,000	\$	55,111,000	\$ 
Liabilities							
Derivative instruments	\$	(65,852,000)	\$		\$	(65,852,000)	\$ 
Total liabilities	\$	(65,852,000)	\$		\$	(65,852,000)	\$ 

The Group's Level 1 securities primarily consist of U.S. Treasury securities, exchange-traded mutual funds, and cash. The Group determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets.

The Group's Level 2 securities primarily consist of U.S. government-sponsored entities' bonds and money market funds. The Group determines the estimated fair value for these Level 2 securities using the following methods: quoted prices for similar assets/liabilities in active markets, quoted prices for identical or similar assets in non-active markets (few transactions, limited information, noncurrent prices, high variability over time), inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curve volatilities, default rates.), and inputs that are derived principally from or corroborated by other observable market data. The

## Notes to Consolidated Financial Statements (continued)

#### **5.** Fair Value Measurements (continued)

System's hedge funds are also considered Level 2 investments because the System has the ability to redeem its investment with the investee at the net asset value per share (or its equivalent) at the measurement date. Redemption can be made on the last day of any calendar quarter with 65 days' advanced written notice.

The Group's Level 2 securities also consist of derivative instruments, which are reported using valuation models commonly used for derivatives. Valuation models require a variety of inputs, including contractual terms, market-fixed prices, inputs from forward price yield curves, notional quantities, measures of volatility, and correlations of such inputs.

The Group also has pledges receivable, which are measured at fair value on a nonrecurring basis and are discounted to the net present value upon receipt using an appropriate risk-free discount rate based on the term of the receivable. Since these inputs are not observable, pledges receivable would be considered Level 3 fair value measurements upon their initial recording. Pledges receivable are recorded net of an allowance for uncollectible pledges. The following table provides a reconciliation of the beginning and ending balances of pledges receivable that used significant unobservable inputs.

	Year Ended June 30				
	2016	2015			
Pledges receivable:					
Balance at July 1	\$ 7,419,000	\$ 9,798,000			
New pledges	2,539,000	1,107,000			
Collections of pledges	(3,203,000)	(3,084,000)			
Write-off of pledges	(517,000)	(454,000)			
Change in reserves	95,000	52,000			
Balance at June 30	\$ 6,333,000	\$ 7,419,000			

## Notes to Consolidated Financial Statements (continued)

### 6. Long-Term Debt and Line of Credit

Long-term debt consists of the following:

	Interest	Maturity	June 30		
	Rate	Dates	2016	2015	
Maryland Health and Higher					
Educational Facilities Authority					
Revenue Bonds – Series 2014	2.0% - 5.0%	2015-2040	\$ 122,580,000	\$ 127,305,000	
Maryland Health and Higher					
Educational Facilities Authority					
Revenue Bonds – Series 2012	2.0% - 5.0%	2013-2035	67,380,000	69,775,000	
Maryland Health and Higher					
Educational Facilities Authority					
Revenue Bonds – Series 2010	4.0%-5.0%	2011-2041	76,430,000	78,145,000	
Maryland Health and Higher					
Educational Facilities Authority			~~ ~~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		
Revenue Bonds – Series 2009B	Variable	2041-2044	60,000,000	60,000,000	
2008 term loan from a bank	Variable	2019	44,795,000	46,748,000	
Kent Island term loan from a bank	Variable	2017	6,788,000	7,134,000	
2008 construction loan from a bank	Variable	2019	23,505,000	24,530,000	
			401,478,000	413,637,000	
Less current portion of					
long-term debt			15,974,000	12,222,000	
Unamortized original issue					
premium, net			11,272,000	11,895,000	
Long-term debt			\$ 396,776,000	\$ 413,310,000	

These debt instruments are secured by the receipts of the Hospital and substantially all of the property and equipment of the consolidated Group.

## Notes to Consolidated Financial Statements (continued)

#### 6. Long-Term Debt and Line of Credit (continued)

Principal payments due under all debt instruments as of June 30, 2016, are as follows:

2017	\$ 15,974,000
2018	9,587,000
2019	68,927,000
2020	6,770,000
2021	7,190,000
Thereafter	293,030,000
	\$ 401,478,000

#### **Series 2014 Revenue Bonds**

In November 2014, the Hospital entered into a loan agreement with the MHHEFA, for the issuance of Series 2014 Revenue Bonds (referred to as the 2014 Bonds). The proceeds of the 2014 Bonds were used to advance refund the Series 2009A Bonds previously provided by MHHEFA. The bonds being refunded were originally obtained to finance a portion of the costs of construction for an eight-story patient care building, two parking garages, and costs related to the issuance. The 2014 Bonds provide for annual principal payments each July 1 from 2015 through 2039. Interest is payable semiannually each July 1 and January 1, beginning in January 2015. The 2014 Bonds bear stated interest rates between 2.00% to 5.00% and were issued at a premium of \$7,520,000, which is amortized over the life of the bonds using the straight-line method, which approximates the effective interest method. The effective annual interest rate for the 2014 Bonds for the years ended June 30, 2016 and 2015, was 4.14% and 2.38%, respectively.

In connection with the advance refunding of the Series 2009A Bonds, the Hospital recognized a loss of \$32,230,000, which is recorded as a loss on advance refunding of debt in the accompanying consolidated statement of operations and changes in net assets for the year ended June 30, 2015. The loss on advance refunding is comprised of a \$29,049,000 prepayment of interest due on the Series 2009A Bonds prior to their call date in 2019 and a \$3,181,000 write-off of deferred financing costs and unamortized bond discount.

## Notes to Consolidated Financial Statements (continued)

#### 6. Long-Term Debt and Line of Credit (continued)

#### **Series 2012 Revenue Bonds**

In October 2012, the Hospital entered into a loan agreement with MHHEFA for the issuance of \$73,625,000 of Series 2012 Revenue Bonds (referred to as the 2012 Bonds). The proceeds of the 2012 Bonds were used to repay the Series 2004A Bonds and the Series 1998 Bonds previously provided by the Authority. The bonds being refinanced were originally obtained to finance a new replacement hospital (Series 1998 Bonds) and to finance major renovations to the Hospital's Cancer Center and land acquisition (Series 2004A Bonds). The 2012 Bonds provide for annual principal payments each July 1 from 2013 through 2034. Interest is payable semiannually on each July 1 and January 1, beginning July 1, 2013. The 2012 Bonds bear stated interest at rates of 2.00% to 5.00%, and were issued at a premium of \$6,746,000. The effective annual interest rates for the 2012 Bonds for the years ended June 30, 2016 and 2015, were 3.71% and 3.75%, respectively.

The provisions of the 2014 and 2012 Bonds, together with the Series 2010 Bonds and Series 2009 Bonds, require the Parent and subsidiaries to comply with certain covenants on an annual basis, including a debt service coverage requirement, a debt-to-capitalization requirement, and a liquidity requirement. The Hospital, the Parent, and HCS are members of the obligated Group for all of the revenue bonds issued by the MHHEFA.

#### **Series 2010 Revenue Bonds**

In February 2010, the Hospital entered into a loan agreement the Revenue Bonds (2010 Bonds) MHHEFA for the issuance of \$85,410,000 of 2010 Bonds. The proceeds of the 2010 Bonds were used to repay the Series 2004B Bonds and dedicated financing previously provided by the HMMEFA and are also being used to finance the expansion of the parking garage for the Hospital's acute care pavilion. The 2010 Bonds provide for annual principal payments each July 1, from 2011 through 2040. Interest is payable semiannually on each July 1 and January 1, beginning July 1, 2010. The 2010 Bonds bear stated interest at rates of 4.00% to 5.00%, and were issued at an original issue discount of \$1,507,000. The effective annual interest rates for the 2010 Bonds for the years ended June 30, 2016 and 2015, were 4.97% and 4.95%, respectively.

### Notes to Consolidated Financial Statements (continued)

#### 6. Long-Term Debt and Line of Credit (continued)

#### **Series 2009 Revenue Bonds**

In January 2009, the Hospital entered into a loan agreement with the MHHEFA for the issuance of \$120,000,000 of Series 2009A Revenue Bonds (the 2009A Bonds) and in February 2009, \$60,000,000 of Series 2009B Revenue Bonds (the 2009B Bonds) (collectively referred to as the 2009 Bonds). The proceeds of the 2014 Bonds were used to advance refund the Series 2009A Bonds previously provided by the MHHEFA. The proceeds of the 2009 Bonds were used to finance a portion of the costs of construction of an eight-story patient care building, two new parking garages, and certain costs relating to the issuance. The 2009A Bonds provided for annual principal payments each July 1 from 2012 through 2039. Interest was payable semiannually on each July 1 and January 1 beginning July 1, 2009. The 2009B Bonds provide for annual principal payments each July 1, from 2040 through 2043. Interest is payable semiannually on each July 1 and January 1, beginning July 1, 2009. The 2009A Bonds bore stated interest at rates of 4.00% to 6.75%. The 2009A Bonds were issued at an original issue discount of \$4,817,000. The effective annual interest rate for the 2009A Bonds for the year ended June 30, 2015, was 2.68%. The 2009B Bonds bear interest at variable rates, as set forth in the loan agreement. The maximum interest rate is 12% for the 2009B Bonds. The effective annual interest rates for the 2009B Bonds for the years ended June 30, 2016 and 2015, were 0.12% and 0.05%, respectively. The principal and interest payments on the Series 2009B Bonds are secured by a letter of credit equal to the original principal of the bonds plus an amount equal to 40 days' interest thereon, calculated at the maximum rate. The current letter of credit expires on July 1, 2020. Under certain circumstances, the Hospital would need to fully redeem the 2009B Bonds upon expiration of the letter of credit, unless a conforming replacement letter of credit was secured prior to such expiration.

The related balances are included in assets whose use is limited and consist of the following:

		June 30				
		2015				
Debt service funds	\$	12,310,000	\$	15,074,000		
Debt service reserve funds		12,543,000		12,517,000		
Construction fund and capitalized interest fund		180,000		211,000		
	\$	25,033,000	\$	27,802,000		

## Notes to Consolidated Financial Statements (continued)

### 6. Long-Term Debt and Line of Credit (continued)

#### **Bank Line of Credit and Term Loan**

The Hospital maintains a line of credit with a bank providing available credit of \$30,000,000. The agreement with the bank is reviewed for renewal on February 28 of each year. Interest on any borrowings accrues at the one-month London Interbank Offered Rate (LIBOR) plus 1.5%. At June 30, 2016 and 2015, the Group has no balance on the line of credit.

On October 23, 2008, the Real Estate Company secured a term loan in the amount of \$55,000,000 with a bank. The proceeds from the term loan were used to refinance line of credit proceeds and fund certain construction costs related to a medical office building. The loan bears interest at a variable rate, based on the LIBOR market index rate plus 1.25%. The term loan requires monthly payments of \$227,000 with all remaining amounts due upon final maturity on November 5, 2018. The effective annual interest rates for the years ended June 30, 2016 and 2015, were 1.72% and 1.43%, respectively.

#### 2008 Construction Loan

On October 23, 2008, the Real Estate Company entered into a construction loan in the amount of \$30,000,000 with a bank to fund the construction of a medical office building. The loan was issued under the same loan agreement as the term loan discussed in the immediately preceding paragraph. The debt is secured by the medical office building. Interest only is due during the construction period at a rate equal to the LIBOR market index rate plus 1.25%. The loan converted to a term loan after the completion of the construction in July 2009. The term loan provides for monthly principal and interest payments and has a final maturity of November 5, 2018. The effective annual interest rates for the years ended June 30, 2016 and 2015, were 1.59% and 1.43%, respectively.

## Notes to Consolidated Financial Statements (continued)

### 6. Long-Term Debt and Line of Credit (continued)

#### Kent Island Term Loan

In August 2007, KIMA entered into a construction loan agreement with a bank in the amount of \$9,000,000 that would convert to a term loan after the completion of the construction. The proceeds were used to construct a medical office building. The debt is secured by the medical office building. Interest only was due during the construction period at a rate of the 30-day LIBOR plus 1.0%. The construction was completed in June 2008. The term loan provides for monthly principal and interest payments and has a final maturity in December 2016. The effective annual interest rate for the years ended June 30, 2016 and 2015, was 1.18%.

#### 7. Pension Plan and Thrift Plan

The Hospital has a qualified noncontributory, defined benefit pension plan (the Plan) that covers substantially all employees. The Group's policy is to fund pension costs as determined by its actuary. Adopted by the Board of Trustees on June 11, 2009, and effective September 1, 2009, the Hospital amended the Plan to freeze future benefit accruals, and participants have not earned any additional benefits under the Plan since that date. However, subsequent to September 1, 2009, participants have continued to vest in benefits they have earned through September 1, 2009. The frozen benefit balance for the participants will only accrue interest credits until the participants' benefit commencement dates. FASB ASC 715, *Compensation — Retirement Benefits*, requires the Group to recognize the funded status (i.e., the difference between the fair value of plan assets and the projected benefit obligations) of its pension plan on its consolidated balance sheet, with a corresponding adjustment to unrestricted net assets. The pension liability adjustment to unrestricted net assets represents the change in net unrecognized actuarial losses that have not yet been recognized as part of revenues and gains in excess of expenses. These amounts are subsequently recognized as a net periodic benefit cost pursuant to the Group's historical accounting policy for amortizing such amounts.

### Notes to Consolidated Financial Statements (continued)

#### 7. Pension Plan and Thrift Plan (continued)

During the year ended June 30, 2015, a partial settlement of the Plan's defined benefit obligation was recognized. Since the settlement was more than minor, ASC 715 requires that a pro rata amount of the accumulated unrecognized net loss in unrestricted net assets be charged to revenues and gains in excess of (less than) expenses based on the proportion of the projected benefit obligation settled to the total projected benefit obligation. During the year ended June 30, 2015, the Group determined that a settlement had occurred and recognized a loss of \$2,927,000. For the year ended June 30, 2015, the settlement loss is recorded within employee benefits in the consolidated statement of operations and changes in net assets. There was no partial plan settlement for the year ended June 30, 2016.

The reconciliation of the beginning and ending balances of the projected benefit obligation and the fair value of plan assets for the years ended June 30, 2016 and 2015, and the accumulated benefit obligation at June 30, 2016 and 2015, is as follows:

	June 30				
		2016	2015		
Accumulated benefit obligation	\$	130,775,000 \$	121,761,000		
Change in projected benefit obligation: Projected benefit obligation at beginning of year Service cost	\$	121,761,000 \$	116,610,000		
Interest cost Actuarial loss		4,931,000 10,589,000	4,419,000 8,123,000		
Benefits paid Settlements paid		(1,652,000) (4,854,000)	(1,426,000) (5,965,000)		
Projected benefit obligation at end of year Change in plan assets:		130,775,000	121,761,000		
Fair value of plan assets at beginning of year Actual return on plan assets		99,059,000 (3,619,000)	97,340,000 (466,000)		
Employer contribution Plan reimbursement Benefits paid		10,247,000 127,000 (1,653,000)	9,576,000 - (1,426,000)		
Settlements paid Fair value of plan assets at end of year		(1,000,000) (4,854,000) 99,307,000	(5,965,000) 99,059,000		
Net liability recognized	\$	(31,468,000) \$	(22,702,000)		

## Notes to Consolidated Financial Statements (continued)

### 7. Pension Plan and Thrift Plan (continued)

	June 30				
	201	16	2015		
Net amounts recognized in the consolidated balance sheets consist of: Accrued pension costs	\$ (31,40	5 <b>8,000</b> ) \$	(22,702,000)		
Amounts recognized in unrestricted net assets that have not been recognized in net periodic benefit costs consist of: Net actuarial loss	\$ 79,82	25,000 \$	59,756,000		

The following table sets forth the weighted average assumptions used to determine the benefit obligations:

	June 30		
	2016 2015		
Discount rate Rate of compensation increase	3.40% N/A	4.15% N/A	

The following table sets forth the weighted average assumptions used to determine the net periodic benefit cost:

	Year Ended June 30			
	2016	2015		
Discount rate	4.15%	3.83%		
Expected return on plan assets	7.50	7.50		
Rate of compensation increase	N/A	N/A		

## Notes to Consolidated Financial Statements (continued)

#### 7. Pension Plan and Thrift Plan (continued)

The net periodic pension benefit cost included the following components:

	June 30			
		2016	2015	
Service cost	\$	- \$	_	
Interest cost		4,931,000	4,419,000	
Expected return on plan assets		(7,830,000)	(7,225,000)	
Amortization of prior service cost		_	_	
Recognized net actuarial loss		1,172,000	1,205,000	
Loss recognized from partial settlement of				
projected benefit obligation		_	2,927,000	
Net periodic (credit) benefit cost	\$	(1,727,000) \$	1,326,000	

The estimated net loss of the defined benefit pension plan that will be amortized from unrestricted net assets into net periodic benefit cost over the next fiscal year is \$2,545,000.

The Hospital's defined benefit plan invests in a diversified mix of traditional asset classes. Investments in certain types of U.S. equity securities and fixed -ncome securities are made to maximize long-term results while recognizing the need for adequate liquidity to meet ongoing benefit and administrative obligations. Risk tolerance of unexpected investment and actuarial outcomes is continually evaluated by understanding the pension plan's liability characteristics. Equity investments are used primarily to increase the overall plan returns. Debt securities provide diversification benefits and liability hedging attributes that are desirable, especially in falling interest rate environments.

The Hospital's target asset allocation percentages as of June 30, 2016, were as follows: 35.0% investment grade bonds, 27.5% international equity, 19.25% large cap domestic stocks, 8.25% small cap domestic stocks, and 10.0% hedge funds and exchange-traded notes.

## Notes to Consolidated Financial Statements (continued)

### 7. Pension Plan and Thrift Plan (continued)

The following tables present the fair value hierarchy of assets of the defined benefit pension plan at June 30.

	June 30, 2016					
		Quoted Prices in Active Markets for Identical Assets	1	Significant Other Observable Inputs	Significant Unobservable Inputs	
	 Total	Level 1		Level 2	Level 3	
Assets						
Cash and cash equivalents	\$ 3,464,000	\$ –	\$	3,464,000	\$ -	
Mutual funds:						
Equity	35,961,000	35,961,000		_	_	
Corporate bonds	14,463,000	14,463,000		_	_	
Government bonds	8,388,000	8,388,000		_	_	
International equity	17,896,000	17,896,000		_	_	
International bonds	9,356,000	9,356,000		_	_	
Exchange-traded notes	5,608,000	5,608,000		_	-	
Managed partnerships:						
Hedge funds	4,171,000	-		4,171,000	_	
	\$ 99,307,000	\$ 91,672,000	\$	7,635,000	\$ -	

## Notes to Consolidated Financial Statements (continued)

#### 7. Pension Plan and Thrift Plan (continued)

June 30, 2015							
		Q			lignificant		
		I		2	Other	5	Significant
			Identical	(	Observable		nobservable
			Assets		Inputs		Inputs
	Total		Level 1		Level 2		Level 3
\$	2,265,000	\$	_	\$	2,265,000	\$	_
	27,587,000		27,587,000		_		_
	5,191,000		5,191,000		_		_
	22,377,000		22,377,000		_		_
	27,632,000		27,632,000		_		_
	5,012,000		5,012,000		_		_
	4,487,000		4,487,000		-		_
	4,508,000		_		4,508,000		_
\$	99,059,000	\$	92,286,000	\$	6,773,000	\$	_
	\$	27,587,000 5,191,000 22,377,000 27,632,000 5,012,000 4,487,000 4,508,000	Total           \$ 2,265,000 \$           \$ 27,587,000           5,191,000           22,377,000           27,632,000           5,012,000           4,487,000           4,508,000	Quoted Prices in Active Markets for Identical Assets           Total         Level 1           \$ 2,265,000         \$ -           27,587,000         27,587,000           5,191,000         5,191,000           22,377,000         22,377,000           27,632,000         5,012,000           4,487,000         4,487,000	Quoted Prices in Active         S           Markets for Identical         Markets for Identical         G           Total         Level 1         C           \$ 2,265,000         \$ - \$         \$           27,587,000         27,587,000         5,191,000           5,191,000         5,191,000         22,377,000           27,632,000         27,632,000         5,012,000           4,487,000         4,487,000         -	Quoted Prices in Active Markets for Identical         Significant Other           Markets for Identical         Significant           Markets for Identical         Observable           Assets         Inputs           Total         Level 1         Level 2           \$ 2,265,000         \$ -         \$ 2,265,000           \$ 2,265,000         \$ -         \$ 2,265,000           \$ 2,265,000         \$ -         \$ 2,265,000           \$ 2,265,000         \$ -         \$ 2,265,000           \$ 2,265,000         \$ -         \$ 2,265,000           \$ 2,265,000         \$ -         \$ 2,265,000           \$ 2,265,000         \$ -         \$ 2,265,000           \$ 2,265,000         \$ -         \$ 2,265,000           \$ 2,265,000         \$ -         \$ 2,265,000           \$ 2,377,000         \$ 2,377,000         -           \$ 2,012,000         \$ 5,012,000         -           \$ 4,487,000         \$ 4,487,000         -           \$ 4,508,000         -         \$ 4,508,000	Quoted Prices in Active         Significant           Markets for Identical         Other         S           Total         Level 1         Level 2           \$ 2,265,000         \$ -         \$ 2,265,000         \$           \$ 2,265,000         \$ -         \$ 2,265,000         \$           \$ 2,265,000         \$ -         \$ 2,265,000         \$           \$ 2,265,000         \$ -         \$ 2,265,000         \$           \$ 2,265,000         \$ -         \$ 2,265,000         \$           \$ 2,265,000         \$ -         \$ 2,265,000         \$           \$ 2,265,000         \$ -         \$ 2,265,000         \$           \$ 2,265,000         \$ -         \$ 2,265,000         \$           \$ 2,265,000         \$ -         \$ 2,265,000         \$           \$ 2,265,000         \$ -         \$ 2,265,000         \$           \$ 2,7,587,000         \$ 2,377,000         -         \$           \$ 27,632,000         \$ 27,632,000         -         \$           \$ 2,012,000         \$ 5,012,000         -         \$           \$ 4,487,000         \$ 4,487,000         -         \$           \$ 4,508,000         -         \$ 4,508,000         -

Level 1 securities primarily consist of exchange-traded mutual funds. Level 2 securities primarily consist of money market funds and hedge funds. Methods consistent with those discussed in Note 5 are used to estimate the fair values of these securities.

The overall expected rate of return on assets assumptions was based on historical returns, with adjustments made to reflect expectations of future returns. The extent to which the future expectations were recognized considered the target rates of returns for the future, which have historically not changed.

The Hospital currently intends to make voluntary contributions to the defined benefit pension plan of \$9,576,000 in fiscal year 2017.

## Notes to Consolidated Financial Statements (continued)

#### 7. Pension Plan and Thrift Plan (continued)

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

2017	\$ 6,293,000
2018	6,408,000
2019	6,995,000
2020	6,964,000
2021	7,716,000
2022–2026	36,867,000

In addition to the noncontributory defined benefit pension plan, the Hospital also offers an employee thrift plan. Participation in the plan is voluntary. Substantially all full-time employees of the Hospital are eligible to participate. Employees may elect to contribute a minimum of 1% of compensation, and a maximum amount as determined by Sections 403(b) and 415 of the Internal Revenue Code. Any employee making contributions to the plan is entitled to a Hospital contribution that will match the employee contribution at the rate of 50% to 75%, depending on the number of years of service, up to a maximum of 4% of qualified compensation. Matching contributions under this thrift plan were \$3,933,000 and \$3,338,000 in fiscal years 2016 and 2015, respectively.

#### 8. Concentrations of Credit Risk

Certain members of the Group grant credit without collateral to their patients, most of whom are local residents and are insured under third-party payor agreements. The mix of receivables from patients and third-party payors prior to consideration of an allowance for doubtful accounts was as follows:

	June	30
	2016	2015
Medicare	25%	28%
Medicaid	6	4
Blue Cross	21	24
Commercial, HMO, PPO, and other	30	29
Patients	18	15
	100%	100%

## Notes to Consolidated Financial Statements (continued)

#### 9. Malpractice Insurance Costs and Self-Insured Professional Liability

Until August 1, 1998, the Group maintained insurance coverage for general and professional liability claims on a claims-made basis. The professional liability coverage included a per-case deductible of \$250,000, up to a maximum out-of-pocket amount of \$750,000 annually. Effective August 1, 1998, the Group changed its professional liability coverage to a full coverage claims-made policy with no annual deductibles. This policy included tail coverage for claims incurred prior to August 1, 1998, but reported subsequently. Effective August 1, 2002, the Group changed its professional liability coverage back to a claims-made policy with a per-case deductible of \$250,000, up to a maximum out-of-pocket amount of \$750,000 annually. Also, the Group did not purchase tail coverage for claims incurred prior to August 1, 2002, that were not yet reported.

Effective March 1, 2004, the Group changed its professional liability coverage to a self-insurance trust with annual exposure limits of \$2,000,000 per claim and \$11,000,000 in the aggregate. The Group carried an excess liability insurance policy for claims above these limits.

Effective July 1, 2005, Cottage was formed as a captive insurer to provide professional liability insurance for the Group. Cottage is a wholly owned subsidiary of the System, which was formed in the Cayman Islands. The primary layer of professional and general liability insurance coverage is self-insured through Cottage and the secondary layer is fully reinsured through several highly rated commercial carriers.

For the period from July 1, 2005 to June 30, 2009, Cottage issued claims-made policies covering Hospital professional liability (including employed physicians) and on an occurrence basis, comprehensive general liability risks of the Parent and certain affiliates. Policy limits were \$2,000,000 per claim with a \$9,000,000 policy aggregate. Effective July 1, 2005, Cottage assumed existing liabilities from the System's self-insured trust discussed above on a claims-made basis. Effective July 1, 2009, Cottage issued a claims-made policy providing \$2,000,000 per claim for Hospital professional liability coverage and \$1,000,000 per claim for comprehensive general liability coverage, subject to a consolidated annual aggregate limit of \$10,000,000.

For the period from July 1, 2005 to June 30, 2008, Cottage also issued an excess umbrella coverage policy (covering Hospital professional liability) with limits of \$20,000,000 per claim with a policy aggregate. For claims reported on and subsequent to July 1, 2008, the coverage limit provided is \$30,000,000 per claim with a policy aggregate. These excess limits are in excess of the primary policy, and the umbrella policies are 100% reinsured with highly rated third-party commercial reinsurers.

### Notes to Consolidated Financial Statements (continued)

#### 9. Malpractice Insurance Costs and Self-Insured Professional Liability (continued)

The provision for estimated professional liability claims, general liability claims, and workers' compensation claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported. As of June 30, 2016 and 2015, the balance for outstanding claims reserves recorded at Cottage is \$21,224,000 and \$22,186,000, respectively. The remaining tail liability for claims incurred but not reported is \$5,114,000 and \$5,357,000 as of June 30, 2016 and 2015, respectively, with \$4,352,000 of the 2016 liability and \$4,527,000 of the 2015 liability recorded at the Hospital. The remainder of the liability is recorded at PE. The Group has employed an independent actuary to estimate the ultimate settlement of such claims. In management's opinion, the amounts recorded provide an adequate reserve for loss contingencies. However, changes in circumstances affecting professional liability claims could cause these estimates to change by material amounts in the short term.

#### **10.** Commitments and Contingencies

#### **Operating Leases**

Various members of the Group have operating leases for storage space, equipment, and offices. During 2016 and 2015, rent expense for these leases was approximately \$10,669,000 and \$10,176,000, respectively. Future minimum annual rental payments under noncancelable operating leases, which expire through 2022, are as follows:

2017	\$ 8,922,000
2018	6,426,000
2019	4,981,000
2020	4,007,000
2021	2,350,000
Thereafter	4,313,000
	\$ 30,999,000

## Notes to Consolidated Financial Statements (continued)

#### 10. Commitments and Contingencies (continued)

#### **Contracted Construction Commitments**

Members of the Group have future construction commitments with outside contractors for various projects totaling \$3,563,000 and \$1,566,000 as of June 30, 2016 and 2015, respectively.

#### Contingencies

Members of the Group have been named as defendants in various legal proceedings arising from the performance of their normal activities. In the opinion of management, after consultation with legal counsel and after consideration of applicable insurance, the amount of the Group's ultimate liability under all current legal proceedings will not have a material adverse effect on its consolidated financial position or results of operations.

The Group's revenues may be subject to adjustment as a result of examination by government agencies or contractors, based upon differing interpretations of government regulations, medical diagnoses, charge coding, medical necessity, or other contract terms. The resolution of these matters, if any, often is not finalized until subsequent to the period during which the services were rendered. Section 302 of the Tax Relief and Health Care Act of 2006 authorized a permanent program involving the use of third-party recovery audit contractors (RACs) to identify Medicare overpayments and underpayments made to providers. Management has established protocols to respond to RAC requests and payment denials. Payment recoveries resulting from RAC reviews are appealable through administrative and judicial processes, and management intends to pursue the reversal of adverse determinations where appropriate. In addition to overpayments that are not reversed on appeal, management will incur additional costs to respond to requests for records and pursue the reversal of payment denials. As of June 30, 2016 and 2015, the Group has recorded an estimated reserve regarding the Medicare overpayments. In the opinion of the Group's management, the ultimate settlement of this matter will not have a material adverse effect on the consolidated financial position of the Group.

## Notes to Consolidated Financial Statements (continued)

#### **11. Functional Expenses**

Members of the Group provide general health care services to residents within their service area. Expenses related to providing these services are as follows:

	Year Ended June 30				
	2016	2015			
Health care services	\$ 522,022,000	\$ 506,771,000			
General and administrative	120,628,000	101,485,000			
	\$ 642,650,000	\$ 608,256,000			

#### **12. Fair Value of Financial Instruments**

The carrying amounts of cash and cash equivalents, patient receivables, prepaid expenses and other current assets, accounts payable, accrued salaries, wages and benefits, other accrued expenses, and advances from third-party payors approximate fair value, given the short-term nature of these financial instruments or their methods of valuation. The following methods and assumptions were used by the Group in estimating the fair value of other financial instruments.

#### Investments and Assets Whose Use Is Limited

Fair values are based on quoted market prices, if available, or estimated using quoted market prices for similar securities.

#### **Pledges Receivable**

The Group estimates that the carrying value of pledges receivable approximates fair value, given the discount rates applied.

#### **Long-Term Debt**

Fair values of the Group's long-term fixed-rate debt are established using discounted cash flow analyses, based on the Group's current incremental borrowing rates for similar types of borrowing arrangements. The carrying amount of the Group's long-term variable-rate debt approximates fair value. The estimated fair value of all long-term debt at June 30, 2016 and 2015, was \$433,667,000 and \$430,763,000, respectively.

## Notes to Consolidated Financial Statements (continued)

#### **13. Temporarily Restricted Net Assets**

At June 30, 2016 and 2015, temporarily restricted net assets are restricted for use, as follows:

	 2016	2015
Hospital capital additions Hospital operating programs	\$ 4,408,000 8,620,000	\$ 6,296,000 8,068,000
riospiul operating programs	\$ 13,028,000	\$ 14,364,000

### 14. Subsequent Events

The Group has evaluated the impact of subsequent events through September 30, 2016, representing the date at which the consolidated financial statements were issued.

Supplementary Information

## Supplementary Consolidating Balance Sheet

#### June 30, 2016

	Anne Arundel	Anne Arundel Medical Center,		Anne Arundel Real Estate Holding Company, Inc.	Cottage Insurance	AAHS Research	Physician	Anne Arundel Medical Center Collaborative	Anne Arundel Medical Center	Consolid Eliminatin Cottage	ng Entries	
	Health System, Inc.	Inc. and Subsidiaries	Enterprises, Inc.	and Subsidiaries	Company, Ltd.	Institute, Inc.	Enterprise, LLC	Care Network, LLC	Foundation, Inc.	Insurance Company, Ltd.	Other Subsidiaries	Consolidated
Assets	System, mc.	Subsidiaries	me.	Subsidiaries	Lia.	mc.	LLC	LLC	me.	Company, Ltu.	Subsidiaries	Consolidated
Current assets:												
Cash and cash equivalents	\$ -	\$ 67,914,000	\$ 5,272,000	\$ 1,471,000	\$ -	\$ 225,000	\$ 486,000	\$ 1,000	\$ 2,305,000	\$ –	\$ - \$	5 77,674,000
Short-term investments	-	3,371,000	-	_	-	-	-	-	425,000	-	-	3,796,000
Current portion of assets whose use is limited	-	12,310,000	-	-	2,061,000	-	-	-	-	-	-	14,371,000
Patient receivables, net	-	62,989,000	-	-	-	-	7,650,000	-	-	-	-	70,639,000
Current portion of pledges receivable, net	-	-	-	-	-	-	-	-	1,296,000	-	-	1,296,000
Inventories	-	8,842,000	93,000	-	-	-	-	-	-	-	-	8,935,000
Prepaid expenses and other current assets	4,127,000	12,109,000	1,423,000	736,000	48,000	52,000	69,000	-	59,000	-	(10,409,000)	8,214,000
Total current assets	4,127,000	167,535,000	6,788,000	2,207,000	2,109,000	277,000	8,205,000	1,000	4,085,000	-	(10,409,000)	184,925,000
Property and equipment	-	682,061,000	14,456,000	135,331,000	_	69,000	651,000	_	1,377,000	-	_	833,945,000
Less accumulated depreciation and amortization		(328,464,000)	(9,544,000)	(50,959,000)	-	(60,000)	(331,000)	-	(253,000)	-	-	(389,611,000)
Net property and equipment		353,597,000	4,912,000	84,372,000	-	9,000	320,000	-	1,124,000	-	-	444,334,000
Other assets:												
Investments	-	245,271,000	-	-	-	-	-	-	1,553,000	-	-	246,824,000
Investments in joint ventures	-	-	411,000	8,306,000	-	-	-	-	-	-	-	8,717,000
Pledges receivable, net	-	-	-	-	-	-	-	-	5,037,000	-	-	5,037,000
Assets whose use is limited	-	13,543,000	-	-	22,686,000	-	-	-	14,213,000	-	-	50,442,000
Deferred debt issue costs, net	-	4,205,000	-	165,000	-	-	-	-	-	-	-	4,370,000
Beneficial interest in net assets of												
Anne Arundel Medical Center Foundation, Inc.	-	24,422,000	-	-	-	-	-	-	-	-	(24,422,000)	-
Restricted collateral for interest rate												
swap contract	-	69,336,000	-	-	-	-	-	-	-	-	-	69,336,000
Investment in subsidiaries and other assets	371,627,000	10,976,000	-	1,663,000	7,523,000	-	1,224,000	-	1,286,000	-	(376,266,000)	18,033,000
Total assets	\$ 375,754,000	\$ 888,885,000	\$ 12,111,000	\$ 96,713,000	\$ 32,318,000	\$ 286,000	\$ 9,749,000	\$ 1,000	\$ 27,298,000	\$ -	\$ (411,097,000) \$	\$ 1,032,018,000

## Supplementary Consolidating Balance Sheet (continued)

#### June 30, 2016

Liabilities and net asets         System, Inc.         Subsidiaries         Inc.         Subsidiaries         LLd.         Inc.         LLC         LLC         Inc.         Company_Ltd.         Subsidiaries         Consolidated           Current liabilities:         Current liabilities: $31,000$ \$         1,9997,000         \$         5,090,000         \$         9,500,000         \$         1,581,000         \$         2,587,000         \$         -         \$         2,800,000         -         2,212,000         0         -         2,212,000         0         -         2,212,000         0         -         2,212,000         -         2,212,000         -         2,212,000         0         -         2,212,000         - <td< th=""><th></th><th>Anne Arundel Health</th><th>Anne Arundel Medical Center, Inc. and</th><th>Enterprises,</th><th>Anne Arundel Real Estate Holding Company, Inc. and</th><th>Cottage Insurance Company,</th><th>AAHS Research Institute,</th><th>Physician Enterprise,</th><th>Anne Arundel Medical Center Collaborative Care Network,</th><th>Anne Arundel Medical Center Foundation,</th><th>Consolida Eliminatir Cottage Insurance</th><th>g Entries Other</th><th></th></td<>		Anne Arundel Health	Anne Arundel Medical Center, Inc. and	Enterprises,	Anne Arundel Real Estate Holding Company, Inc. and	Cottage Insurance Company,	AAHS Research Institute,	Physician Enterprise,	Anne Arundel Medical Center Collaborative Care Network,	Anne Arundel Medical Center Foundation,	Consolida Eliminatir Cottage Insurance	g Entries Other	
Current labilities: Accounts payable\$ 158,000 \$ 17,157,000 \$ 7,09,000 \$ 508,000 \$ 1,088,000 \$ 1,088,000 \$ 1,573,000 \$ 1,581,000 \$ 2,587,000 \$ - \$ 0,889,000 \$ 1,901,000 Accrued sharks, wages, and benefits - 19,997,000 1,490,000 75,000 5,695,000 - 28,000 - 28,000 - 28,000 - 27,285,000 Current portion of long-term debt - 21,241,000 225,000 - 10,294,000 261,000 - 26,000 - 26,000 15,974,000 Advances from thich-party payors Total current labilitiesS 158,000 8 5,956,000 - 10,294,000 260,000 - 2,876,000 24,655,000 - 2,200,000 - 2,287,000 260,000 - 2,876,000 - 2,95,85,000		System, Inc.	Subsidiaries	Inc.	Subsidiaries	Ltd.	Inc.	LLC	LLC	Inc.	Company, Ltd.	Subsidiaries	Consolidated
Accounts payable       \$ 158,000       \$ 17,157,000       \$ 7,099,000       \$ 508,000       \$ 1,088,000       \$ 95,000       \$ 1,581,000       \$ 2,587,000       \$ -       \$ 6,988,9000       \$ 1,901,000         Accrued satries, wages, and benefits       -       19,997,000       1,490,000       -       -       75,000       \$ 2,587,000       \$ -       \$ 6,988,9000       \$ 1,901,000         Other accrued express       -       2,21,241,000       22,2000       610,000       -       -       -       -       261,000       -       -       24,655,000         Advances from third-party payors       -       62,00,000       -       11,412,000       3,406,000       170,000       4,322,000       1,581,000       2,876,000       -       -       -       -       -       -       2,2001,000       15,974,000       15,974,000       15,974,000       15,974,000       15,974,000       15,974,000       15,974,000       15,980,000       -													
Accrued salaries, wages, and benefits-19,997,0001,490,00075,0005,695,000-28,00027,285,000Other accrued expenses-21,241,000225,000610,0002,318,00026,00024,655,000Current portion of long-term debt-6,200,00022,001,000Total current liabilities158,00086,596,0008,814,00011,412,0003,406,000170,0004,322,0001,581,0002,876,000-010,8926,000Interest rate swap contract-99,585,00099,585,000Accrued pension liability-31,462,00099,585,000Accrued pension liability-31,468,00099,585,000Accrued pension liabilities99,585,000Other long-term liabilities99,585,000Other long-term liabilities99,585,000Other long-term liabilities </td <td></td>													
Other accrued expenses         -         21,241,000         225,000         610,000         2,318,000         -         -         -         261,000         -         -         24,655,000           Current portion of long-term debt         -         6.20,01,000         -         10,294,000         -         -         -         -         -         -         -         -         24,655,000         15,974,000           Advances from third-party payors         -         22,001,000         3,406,000         170,000         4,322,000         1,581,000         2,876,000         -         010,409,000         108,926,000           Long-term debt, less current portion and unamorized original issue premium         -         331,462,000         -         68,953,000         -         -         -         -         -         01,049,000         396,776,000           Interest rate swap contract         -         99,585,000         -         -         -         -         -         -         -         99,585,000           Acrued pension liability         -         31,462,000         -         -         -         -         -         1,040,000         1,896,000           Other long-term liabilities         -         -         1,000,000	1.5	\$ 158,000			\$ 508,000 \$	1,088,000	,	())	\$ 1,581,000	,,	\$ -	\$ (9,889,000) \$	
Current portion of long-term debt $   -$ <td></td> <td>-</td> <td></td> <td></td> <td></td> <td></td> <td>75,000</td> <td>5,695,000</td> <td>-</td> <td></td> <td>-</td> <td>-</td> <td></td>		-					75,000	5,695,000	-		-	-	
Advances from third-party payors $   -$	1	-	, ,	225,000	,	2,318,000	-	-	-	261,000	-		
Total current liabilities158,000 $86,596,000$ $8,814,000$ $11,412,000$ $3,406,000$ $170,000$ $4,322,000$ $1,581,000$ $2,876,000$ $-$ (10,409,000)108,926,000Long-term debt, less current portion and unamortized original issue premium $ 331,462,000$ $  -$		-	-, -,	-	10,294,000	-	-	-	-	-	-	(520,000)	- , ,
Long-term debt, less current portion and unamortized original issue premium $-331,462,000$ $-68,953,000$ $  -$			,,								-		
unamortized original issue premium         -         331,462,000         -         68,953,000         -	Total current liabilities	158,000	86,596,000	8,814,000	11,412,000	3,406,000	170,000	4,322,000	1,581,000	2,876,000	-	(10,409,000)	108,926,000
Accrued pension liability Other long-term liabilities       -       31,468,000       -       -       -       -       -       -       -       31,468,000         Other long-term liabilities       -       31,468,000         Other long-term liabilities       -       -       -       -       -       -       -       -       -       -       -       31,468,000       19,667,000       19,667,000       19,667,000       19,667,000       19,667,000       19,667,000       15,80,00       15,80,00       549,111,000       8,814,000       81,365,000       22,312,000       170,000       5,083,000       1,581,000       2,876,000       -       -       -       -       0,056,000       1,667,000       656,422,000       656,422,000       10,006,000       116,000       4,666,000       (1,580,000)       1,148,000       -       (348,697,000)       351,518,000       351,518,000       351,518,000       310,280,000       -       -       -       -       -       10,246,000       -       (	unamortized original issue premium	-			68,953,000	-	_	-	-	-			
Other long-term liabilities         -         -         1,000,000         18,906,000         -         761,000         -         -         -         -         (1,000,000)         19,667,000           Total liabilities         158,000         549,111,000         8,814,000         81,365,000         22,312,000         170,000         5,083,000         1,581,000         2,876,000         -         (15,048,000)         656,422,000           Net assets:         Unrestricted         351,518,000         315,696,000         3,297,000         15,348,000         116,000         4,666,000         (1,580,000)         1,148,000         -         (348,697,000)         351,518,000           Temporarily restricted         13,028,000         13,028,000         -         -         -         -         13,028,000         -         (21,296,000)         13,028,000         -         (21,296,000)         13,028,000         -         (21,296,000)         11,050,000         11,050,000         11,050,000         -         -         -         -         10,246,000         -         (21,296,000)         11,050,000         11,050,000         11,050,000         11,050,000         11,050,000         11,050,000         -         -         -         -         -         10,246,000         - <td>1</td> <td>_</td> <td></td> <td></td> <td>_</td> <td>_</td> <td>_</td> <td>_</td> <td>_</td> <td>_</td> <td>_</td> <td>_</td> <td> , ,</td>	1	_			_	_	_	_	_	_	_	_	, ,
Total liabilities       158,000       549,111,000       8,814,000       81,365,000       22,312,000       170,000       5,083,000       1,581,000       2,876,000       -       (15,048,000)       656,422,000         Net assets:       Unrestricted       351,518,000       315,696,000       3,297,000       15,348,000       110,000,000       116,000       4,666,000       (1,580,000)       1,148,000       -       (348,697,000)       351,518,000         Temporarily restricted       13,028,000       -       -       -       -       -       13,028,000       -       (26,056,000)       13,028,000       13,028,000       -       (21,296,000)       13,028,000       -       (21,296,000)       11,050,000       11,050,000       11,050,000       -       -       -       -       -       10,246,000       -       (21,296,000)       11,050,000       11,050,000       11,050,000       11,050,000       11,050,000       -       -       -       -       -       -       -       -       -       -       -       10,246,000       -       (21,296,000)       11,050,000       11,050,000       11,050,000       -       -       -       -       -       -       -       -       -       -       -       -	1 5	_			1 000 000	18 906 000	_	761.000	_	_	_	(1,000,000)	
Unrestricted         351,518,000         315,696,000         3,297,000         15,348,000         110,000         116,000         4,666,000         (1,580,000)         1,148,000         -         (348,697,000)         351,518,000           Temporarily restricted         13,028,000         13,028,000         -         -         -         -         -         13,028,000         -         (26,056,000)         13,028,000         -         13,028,000         13,028,000         -         -         -         -         -         13,028,000         -         (26,056,000)         13,028,000         13,028,000         13,028,000         -         -         -         -         -         -         (21,296,000)         13,028,000         13,028,000         11,050,000         11,050,000         116,000         4,666,000         (1,580,000)         24,422,000         -         (21,296,000)         375,596,000           Total net assets         375,596,000         339,774,000         3,297,000         15,348,000         110,000         116,000         4,666,000         (1,580,000)         24,422,000         -         (396,049,000)         375,596,000		158,000	549,111,000	8,814,000	,,	, ,	170,000	,	1,581,000	2,876,000	_	( ) = = ; = = ; ;	
Temporarily restricted       13,028,000       -       -       -       -       -       -       13,028,000       -       13,028,000       -       13,028,000       -       -       -       -       -       13,028,000       -       13,028,000       -       13,028,000       -       -       -       -       -       -       13,028,000       -       13,028,000       13,028,000       13,028,000       -       0 <th0< th=""> <th0< th=""></th0<></th0<>	Net assets:												
Permanently restricted         11,050,000         11,050,000         -         -         -         -         -         10,246,000         -         (21,296,000)         11,050,000           Total net assets         375,596,000         339,774,000         3,297,000         15,348,000         10,006,000         116,000         4,666,000         (1,580,000)         24,422,000         -         (396,049,000)         375,596,000	Unrestricted	351,518,000	315,696,000	3,297,000	15,348,000	10,006,000	116,000	4,666,000	(1,580,000)	1,148,000	-	(348,697,000)	351,518,000
Total net assets 375,596,000 339,774,000 3,297,000 15,348,000 10,006,000 116,000 4,666,000 (1,580,000) 24,422,000 - (396,049,000) 375,596,000	Temporarily restricted	13,028,000	13,028,000	-	-	-	-	-	-	13,028,000	-	(26,056,000)	13,028,000
	Permanently restricted	11,050,000	11,050,000	-	-	-	-	-	-	10,246,000	-	(21,296,000)	11,050,000
Total liabilities and net assets \$ 375.754.000 \$ 888.885.000 \$ 12.111.000 \$ 96.713.000 \$ 32.318.000 \$ 9.749.000 \$ 1.000 \$ 27.298.000 \$ - \$ (411.097.000) \$ 1.032.018.000	Total net assets	375,596,000	339,774,000	3,297,000	15,348,000	10,006,000	116,000	4,666,000	(1,580,000)	24,422,000	-	(396,049,000)	375,596,000
	Total liabilities and net assets	\$ 375,754,000	\$ 888,885,000	\$ 12,111,000	\$ 96,713,000 \$	32,318,000	\$ 286,000	\$ 9,749,000	\$ 1,000	\$ 27,298,000	\$ -	\$ (411,097,000) \$	\$ 1,032,018,000

## Supplementary Consolidating Schedule of Revenues, Expenses, Gains, and Losses

#### Year Ended June 30, 2016

	Anne Arundel Health System, Inc.	Anne Arundel Medical Center, Inc. and Subsidiaries	Anne Arundel Health Care Enterprises, Inc.	Anne Arundel Real Estate Holding Company, Inc. and Subsidiaries	Cottage Insurance Company, Ltd.	AAHS Research Institute,	Physician Enterprise, LLC	Anne Arundel Medical Center Collaborative Care Network, LLC	Anne Arundel Medical Center Foundation, Inc.	Consolidat Eliminatin; Cottage Insurance Company, Ltd.	g Entries Other	Consolidated
Operating revenue:	System, Inc.	Subsidiaries	mc.	Subsidiaries	Liu.	Inc.	LLC	LLC	mc.	Company, Ltd.	Subsidiaries	Consolidated
Net patient service revenue	s –	\$ 551.363.000	s –	\$ - \$	_	s – :	\$ 100,500,000	s –	\$ -	s –	s – s	651,863,000
Provision for bad debts	ф —	(12,702,000)	ф	φ – φ _		ф — . _	(3,420,000)	ф —	φ – _	ф —	» – »	(16,122,000)
Net patient service revenue, less provision for bad debts		538,661,000	-	_	_	_	97,080,000	-	_	_		635,741,000
Other operating revenue	1,473,000	12,401,000	13,845,000	21,851,000	2,965,000	1,552,000	24,670,000	-	6,042,000	(2,965,000)	(49,886,000)	31,948,000
Total operating revenue	1,473,000	551.062.000	13,845,000	21,851,000	2,965,000	1,552,000	121,750,000	-	6.042.000	(2,965,000)	(49,886,000)	667.689.000
Total operating revenue	1,475,000	551,002,000	15,645,000	21,851,000	2,905,000	1,552,000	121,750,000	-	0,042,000	(2,905,000)	(49,880,000)	007,089,000
Operating expenses:												
Salaries and wages	_	196.309.000	6,260,000	_	_	1.207.000	86,661,000	151.000	867,000	_	_	291,455,000
Employee benefits	_	35,240,000	938,000	_	_	164,000	6,889,000	31,000	114,000	_	_	43,376,000
Supplies	_	133,533,000	114.000	15,000	_	8.000	6.313.000	10.000	8.000	_	_	140.001.000
Purchased services	986,000	112,262,000	5,425,000	10,922,000	1,549,000	600,000	33,989,000	1,389,000	1,589,000	(2,965,000)	(46,645,000)	119,101,000
Foundation transfer to Anne Arundel Medical Center	,000	112,202,000	5,425,000	10,722,000	1,549,000	000,000	55,767,000	1,509,000	1,505,000	(2,705,000)	(40,045,000)	119,101,000
Foundation. Inc. and subsidiaries	_	_	_	_	_	_	_	_	3,172,000	_	(3,172,000)	_
Depreciation and amortization	_	29,507,000	1.134.000	4.631.000	_	8.000	71.000	_	26,000	_	(5,172,000)	35,377,000
Interest	_	12,145,000	1,154,000	1.264.000	_	0,000	/1,000	_	20,000	_	(69,000)	13,340,000
Total operating expenses	986.000	518,996,000	13,871,000	16.832.000	1.549.000	1.987.000	133,923,000	1.581.000	5,776,000	(2,965,000)	(49,886,000)	642,650,000
Operating income (loss)	487.000	32,066,000	(26,000)	5,019,000	1,416,000	(435,000)	(12,173,000)	(1,581,000)	266,000	(2,)05,000)	(4),000,000)	25,039,000
operating meone (1033)	407,000	52,000,000	(20,000)	5,017,000	1,410,000	(455,000)	(12,175,000)	(1,501,000)	200,000			25,057,000
Other income (loss):												
Investment income, net	-	13,307,000	-	21.000	1.015.000	_	-	-	48,000	_	_	14.391.000
(Loss) income from joint ventures and other, net	(20,658,000)	487,000	38,000	(513,000)		_	_	-	11,000	_	20,658,000	23,000
Change in unrealized losses on trading	( .,,	,	,	(					,		.,	- ,
securities, net	-	(18,215,000)	_	-	(1,266,000)	-	-	-	(88,000)	-	-	(19,569,000)
Realized and unrealized losses on												
interest rate swap contracts, net	-	(40,055,000)	-	-	-	_	-	-	-	-	-	(40,055,000)
Total other (loss) income, net	(20,658,000)	(44,476,000)	38,000	(492,000)	(251,000)	-	-	-	(29,000)	-	20,658,000	(45,210,000)
Revenues and gains (less than) in excess of expenses	\$ (20,171,000)	\$ (12,410,000)	\$ 12,000	\$ 4,527,000 \$	1,165,000	\$ (435,000) 3	\$ (12,173,000)	\$ (1,581,000)	\$ 237,000	\$ -	\$ 20,658,000 \$	(20,171,000)
- · · · · · · · · · · · · · · · · · · ·												

## Anne Arundel Medical Center, Inc. and Subsidiaries

# Supplementary Consolidating Balance Sheet

## June 30, 2016

	Anne Arundel Medical Center, Inc.	Anne Arundel Health Care Services, Inc.	Anne Arundel General Treatment	Consolidating and Eliminating Entries	Consolidated
Assets		· · · · · · · · · · · · · · · · · · ·			
Current assets:					
Cash and cash equivalents	\$ 34,592,000	\$ 33,321,000	\$ 1,000	\$ –	\$ 67,914,000
Short-term investments	3,371,000	-	-	_	3,371,000
Current portion of assets whose use is limited	12,310,000	_	_	_	12,310,000
Patient receivables, net	59,872,000	2,600,000	517,000	_	62,989,000
Inventories	8,842,000	_	-	_	8,842,000
Due from affiliates, net	6,258,000	30,659,000	2,623,000	(33,282,000)	6,258,000
Prepaid expenses and other current assets	5,703,000	147,000	1,000	_	5,851,000
Total current assets	130,948,000	66,727,000	3,142,000	(33,282,000)	167,535,000
Property and equipment	649,679,000	26,127,000	6,255,000	_	682,061,000
Less accumulated depreciation and amortization	(302,076,000)	(22,793,000)	(3,595,000)	_	(328,464,000)
Net property and equipment	347,603,000	3,334,000	2,660,000	_	353,597,000
Other assets:					
Investments	245,271,000	_	_	_	245,271,000
Assets whose use is limited	13,543,000	_	_	_	13,543,000
Deferred debt issue costs, net	4,205,000	_	_	_	4,205,000
Beneficial interest in net assets of					
Anne Arundel Medical Center Foundation, Inc.	24,422,000	_	_	_	24,422,000
Notes receivable from affiliate	3,639,000	_	_	_	3,639,000
Restricted collateral for interest rate swap	, , ,				, ,
contract	69,336,000	_	_	_	69,336,000
Investments in subsidiaries and other assets, net	81,042,000	_	_	(73,705,000)	7,337,000
Total assets	\$ 920,009,000	\$ 70,061,000	\$ 5,802,000	\$ (106,987,000)	\$ 888,885,000

## Anne Arundel Medical Center, Inc. and Subsidiaries

# Supplementary Consolidating Balance Sheet (continued)

## June 30, 2016

Anne Arundel Medical Center,	Anne Arundel Health Care	Anne Arundel General	Consolidating and Eliminating	
Inc.	Services, Inc.	Treatment	Entries	Consolidated
\$ 15,744,000	\$ 1,401,000	\$ 12,000	\$ –	\$ 17,157,000
19,252,000	517,000	228,000	-	19,997,000
21,241,000	_	_	_	21,241,000
6,200,000	_	_	_	6,200,000
33,282,000	-	_	(33,282,000)	_
22,001,000	_	_	_	22,001,000
117,720,000	1,918,000	240,000	(33,282,000)	86,596,000
331,462,000	_	_	_	331,462,000
99,585,000	_	_	_	99,585,000
31,468,000	_	_	_	31,468,000
580,235,000	1,918,000	240,000	(33,282,000)	549,111,000
315,696,000	68.143.000	5,562,000	(73,705,000)	315,696,000
			_	13,028,000
	_	_	_	11,050,000
	68 143 000	5 562 000	(73 705 000)	339,774,000
				\$ 888,885,000
	Medical Center, Inc.           \$ 15,744,000           19,252,000           21,241,000           6,200,000           33,282,000           22,001,000           117,720,000           331,462,000           99,585,000           31,468,000	Medical Center, Inc.Health Care Services, Inc. $\$$ 15,744,000 $\$$ $$$ 15,744,000 $\$$ $19,252,000$ 517,000 $21,241,000$ $ 6,200,000$ $ 33,282,000$ $ 22,001,000$ $ 117,720,000$ $1,918,000$ $331,462,000$ $ 31,468,000$ $ 580,235,000$ $1,918,000$ $315,696,000$ $68,143,000$ $13,028,000$ $ 339,774,000$ $68,143,000$	Medical Center, Inc.Health Care Services, Inc.General Treatment $\$$ 15,744,000 $\$$ 1,401,000 $\$$ $\$$ 15,744,000 $\$$ 1,401,000 $\$$ 19,252,000517,000228,00021,241,0006,200,00033,282,00022,001,000117,720,0001,918,000240,000331,462,00099,585,00031,468,000580,235,0001,918,000240,000315,696,00068,143,0005,562,00013,028,000339,774,00068,143,0005,562,000	Medical Center, Inc.Health Care Services, Inc.General Treatmentand Eliminating Entries $\$$ 15,744,000 $\$$ 1,401,000 $\$$ 12,000 $\$$ $-$ 19,252,000517,000228,000 $  -$ 21,241,000 $   -$ 6,200,000 $   -$ 33,282,000 $   -$ 22,001,000 $   -$ 117,720,0001,918,000240,000(33,282,000)331,462,000 $       31,462,000$ $       313,462,000$ $       313,462,000$ $       313,462,000$ $       315,696,000$ $68,143,000$ $5,562,000$ $(73,705,000)$ $13,028,000$ $       339,774,000$ $68,143,000$ $5,562,000$ $(73,705,000)$

## Anne Arundel Medical Center, Inc. and Subsidiaries

# Supplementary Consolidating Schedule of Revenues, Expenses, Gains, and Losses

## Year Ended June 30, 2016

	Anne Arundel Medical Center,		Anne Arundel Health Care			Anne Arundel General	Consolidating and Eliminating		
		Inc.	S	ervices, Inc.		Treatment		Entries	Consolidated
Operating revenue:									
Net patient service revenue	\$	515,424,000	\$	31,065,000	\$	4,874,000	\$	-	\$ 551,363,000
Provision for bad debts		(11,218,000)		(1,220,000)		(264,000)		_	(12,702,000)
Net patient service revenue, less provision for bad debts		504,206,000		29,845,000		4,610,000		_	538,661,000
Other operating revenue		12,303,000		301,000		256,000		(459,000)	12,401,000
Total operating revenue		516,509,000		30,146,000		4,866,000		(459,000)	551,062,000
Operating expenses:									
Salaries and wages		187,550,000		5,672,000		3,087,000		_	196,309,000
Employee benefits		33,821,000		906,000		513,000		_	35,240,000
Supplies		132,213,000		1,063,000		321,000		(64,000)	133,533,000
Purchased services		96,960,000		14,866,000		831,000		(395,000)	112,262,000
Depreciation and amortization		28,332,000		993,000		182,000		_	29,507,000
Interest		12,145,000		_		_		_	12,145,000
Total operating expenses		491,021,000		23,500,000		4,934,000		(459,000)	518,996,000
Operating income		25,488,000		6,646,000		(68,000)		_	32,066,000
Other income (loss):									
Investment income, net		13,307,000		_		_		_	13,307,000
Income from joint venture and other, net		7,065,000		_		-		(6,578,000)	487,000
Change in unrealized losses on trading securities, net		(18,215,000)		_		_		_	(18,215,000)
Realized and unrealized losses on interest rate swap									
contracts, net		(40,055,000)				-		_	(40,055,000)
Total other loss, net		(37,898,000)		_		_		(6,578,000)	(44,476,000)
Revenues and gains (less than) in excess of expenses	\$	(12,410,000)	\$	6,646,000	\$	(68,000)	\$	(6,578,000)	\$ (12,410,000)

## Supplementary Description of Consolidating and Eliminating Entries

- 1. To eliminate intercompany payables and receivables.
- 2. To eliminate investments in subsidiaries and related net asset accounts.
- 3. To eliminate intercompany income and expense generated from management fees, staffing contracts, captive insurance premiums, and operating leases.
- 4. To eliminate intercompany notes.
- 5. To eliminate income of wholly owned subsidiaries.
- 6. To eliminate intercompany revenue and expense for interest and other miscellaneous transactions.
- 7. To eliminate the Hospital's beneficial interest in the Foundation.

#### EY | Assurance | Tax | Transactions | Advisory

#### About EY

EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. For more information about our organization, please visit ey.com.

© 2016 Ernst & Young LLP. All Rights Reserved.

#### ey.com

